Neutralizing AVP monoclonal antibody (COR-2007)
Corteria Pharmaceuticals develops a neutralizing vasopressin human monoclonal IgG1 that bears the potential to cure hyponatremic acute heart failure. It is expected to normalize natremia and improve cardiac and renal functions through the simultaneous absence of systemic activation of V1a, V1b and V2 receptors. Proof of concept has been established in preclinical hyponatremic acute heart failure models. The clinical candidate has been nominated and CMC activities enabling regulatory safety studies are ongoing.